- **Title:** The diagnostic value of plasma phosphorylated tau 181 in Alzheimer's disease 1
- within the Chinese population: A systematic review and meta-analysis 2
- **Authors:** Keqiang Yan<sup>1,2,3</sup>, Shuxin He<sup>1,2</sup>, Xiaodong Jia<sup>1,2</sup>, Haiyan Li<sup>1,2</sup>, Dequan 3
- Liu<sup>1,2\*+</sup>, Jianchun Chen<sup>1,2\*+</sup> 4

#### **Affiliations:** 6

5

11

17 18

41

- 7 <sup>1</sup>Tianjin Kingmed Diagnostics Laboratory Co.Ltd, Tianjin, China.
- <sup>2</sup>Tianjin Key Laboratory of Multi-omics Precision Diagnosis Technology for 8
- Neurological Diseases, Tianjin, China. 9
- <sup>3</sup>Tianjin Medical University, Tianjin, China 10
- <sup>+</sup>Contributed equally 12
- 13 \*Corresponding author
- Email: tianj-liudequan@kingmed.com.cn 14
- Address: Building B, Building 3, Sanwu Internet Technology Park, Binhai High-tech 15
- 16 Zone, Tianjin

## **Abstract**

- Among all related biomarkers, plasma phosphorylated tau (p-tau181) has 19
- demonstrated strong diagnostic performance in the very early stages of Alzheimer's 20
- disease (AD), showing significant differences between AD patients and healthy 21
- controls. The aim of our present systematic review and meta-analysis was to roundly 22
- 23 evaluate the clinical diagnostic value of plasma p-tau181 based on the Simoa platform
- in Chinese populations. We systematically searched five databases (Embase, PubMed, 24
- Cochrane Library, MEDLINE, and Web of Science) from inception to May 11th, 2024, 25
- as well as the references of retrieved relevant articles. We included prospective cohort 26
- studies and retrospective case-control studies in our analysis. Out of 1165 identified 27
- 28 articles, 10 met the inclusion criteria for meta-analysis. Our quantitative analysis
- 29 showed that plasma p-tau181 levels were significantly increased in patients with AD
- and mild cognitive impairment (MCI) compared to healthy controls (standard mean 30
- difference [SMD]: 1.45 [1.25 1.65], p<0.00001; SMD: 0.55 [0.31 0.78], 31
- p<0.00001) and were lower in MCI patients compared to AD patients (SMD: -0.88 32
- 33 [-0.93 - 0.82], p<0.00001). The reference values for plasma p-tau181 were 4.48
- [95% confidence interval (CI): 4.01 5.00] for AD patients, 2.86 [95% CI: 2.45 -34
- 3.34] for MCI patients, and 2.09 [95% CI: 1.90 2.30] for healthy controls. The 35
- meta-analysis confirmed that plasma p-tau181 significantly increases from healthy 36
- controls to mild cognitive impairment (MCI) and then to AD in the Chinese 37
- population. We also provide reliable reference values for plasma p-tau181, which 38
- contribute to the early diagnosis of AD in Chinese clinical settings. 39
- 40 **Keywords:** meta-analysis, p-tau181, Alzheimer's disease

# Introduction

42

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and a 43 leading cause of dementia worldwide<sup>[1]</sup>. First identified by Dr. Alois Alzheimer in 44 1901, AD has since posed significant challenges to the medical community, with no 45 46 cure currently available<sup>[2]</sup>. The 2011 National Institute Aging-Alzheimer's Association (NIA-AA) Diagnostic Criteria conceptualize AD as a 47 continuum encompassing three stages: an asymptomatic phase (preclinical AD), a 48 predementia phase (mild cognitive impairment due to AD), and a dementia phase 49 (dementia due to AD)<sup>[3-5]</sup>. Pathophysiological changes in AD can commence 15 to 20 50 years prior to the manifestation of clinical symptoms, underscoring the critical 51 52 importance of early diagnosis and timely intervention to potentially slow disease progression<sup>[6]</sup>. 53

Recent studies have focused on the early detection of AD through the use of fluid biomarkers<sup>[7]</sup>. Tau proteins, which are microtubule-binding proteins, play an essential role in maintaining neuronal stability and morphology under normal conditions. The regional progression of brain atrophy in AD is closely associated with the accumulation of Tau proteins<sup>[8]</sup>. Hyperphosphorylated Tau (p-tau), in its full-length or truncated forms, represents a key pathological hallmark of AD, exhibiting over 70 post-translational modifications, including more than 40 phosphorylation sites. Various forms of p-tau can be measured in cerebrospinal fluid (CSF) and plasma<sup>[9]</sup>. Among these, p-tau181 is significantly elevated in the CSF of AD patients and is considered a critical biomarker for the disease<sup>[10]</sup>. The ability of p-tau181 to differentiate AD from other neurodegenerative conditions, such as frontotemporal lobar degeneration (FTLD-TDP) and chronic traumatic encephalopathy (CTE), is crucial for the accurate diagnosis of AD<sup>[11]</sup>. Furthermore, p-tau181 levels correlate with AD severity and predict disease progression, providing valuable insights for evaluating therapeutic efficacy and guiding treatment strategies. Recent findings indicate that p-tau181 have excellent discriminative performance in plasma, paving the way for non-invasive monitoring of AD<sup>[12-15]</sup>.

Advancements in technology, such as the Single-molecule Array (Simoa), have enabled the detection of plasma p-tau181 at low concentrations<sup>[16]</sup>. The US FDA has granted breakthrough medical device clearance to this technology, recognizing it as a valuable tool for diagnosing AD through the detection of p-tau181 biomarkers in blood<sup>[17-18]</sup>. Currently, this technique is also widely used in the clinical diagnosis of AD in China. Despite the proven diagnostic value of plasma p-tau181, a large amount of literature with inconsistent conclusions has confused our understanding of this field[19-24]. There is a notable lack of accurate clinical reference values that can distinguish AD from healthy elderly individuals. Previous studies, including one by Ding et al., have attempted to address this by comparing the range of p-tau181 between AD patients and healthy individuals through meta-analysis<sup>[25]</sup>. However, these studies predominantly collected data from European and American populations, which may not be applicable to other populations due to quantitative differences in

- p-tau181 levels among different races and ethnicities. Howell et al. found that older 84
- African Americans had lower CSF levels of p-tau181 compared to older Caucasians, 85
- even after adjusting for demographic variables, genetic factors, and cognitive 86
- function<sup>[26]</sup>. This suggests that there may be race-associated differences in CSF 87
- p-tau181 marker, which also exist in plasma. 88
- 89 To address this gap, the primary objective of the present study is to conduct an
- extensive and comprehensive meta-analysis to determine the distribution of plasma 90
- p-tau181 levels in both healthy individuals and patients with AD and other 91
- neurodegenerative diseases within the Chinese population. Our aim is to provide more 92
- precise and reliable cut-off thresholds for clinical use, thereby improving the accuracy 93
- of AD and other neurodegenerative disease diagnoses and facilitating early screening 94
- 95 in Chinese clinical settings.

## **Methods**

96

97

98

102

103

104

105

106

107 108

109

110

120 121

# Search strategy and study selection

- This meta-analysis was conducted in accordance with the Preferred Reporting Items 99 for a Systematic Review and Meta-analysis (PRISMA) guidelines. The analysis 100
- questions were designed according to the PICOS framework: 101
  - •Participants: clinically diagnosed AD patients; •Intervention: evaluation of plasma p-tau181levels;
  - •Comparison: patients clinically diagnosed with non-AD dementia and cognitively unimpaired participants;
  - •Outcome: normal range of plasma p-tau181 levels in healthy Chinese populations and the efficacy of plasma p-tau181 in differentiating AD from cognitively unimpaired participants or non-AD dementia patients, based on plasma p-tau181 level discrepancies;
    - •Study design: original, observational cross-sectional and prospective studies.
- A literature search was conducted across five databases (Embase, PubMed, Cochrane 111
- Library, MEDLINE and Web of Science) on the date of May 11th, 2024, using the 112
- following search terms: plasma phosphorylated tau, Alzheimer disease, AD, Chinese 113
- 114 and Simoa. Candidate studies were included or excluded based on the following
- criteria: (1) full text publications written in English; (2) plasma p-tau181 levels 115
- measured using Simoa; (3) Study population consisting of Chinese individuals; (4) 116
- AD diagnosed according to the 2011 and 2018 NIA-AA criteria[27] or the 1984 117
- NINCDS-ADRDA criteria<sup>[28]</sup>. Studies were excluded if non-quantitative methods 118
- were employed to assess biomarker levels in the samples. 119

## Data extraction and quality assessment

- Data of interest were independently extracted by two authors (Shuxin He and Keqiang 122
- Yan). Study quality was evaluated using the modified version of the 123
- Newcastle-Ottawa Scale (NOS)<sup>[29]</sup>. A maximum of eight points per study was given 124
- according to the quality of population selection, group comparability and exposure 125
- 126 assessment. Disagreements regarding study selection or data extraction were resolved

by additional reviewers (Xiaodong Jia or Haiyan Li).

### Statistical analysis

127 128

129

130

131 132

133

134

135

136

137 138

139

140

141

142

143

144

145

146

147 148

149

150

151

152

153

154 155

156

157

158

159

160

161

162

163

164

166

A random-effects model meta-analysis was employed to calculate the pooled effect size across multiple studies<sup>[31]</sup>. The normal range of plasma p-tau181 and standardized mean difference (SMD) between dementia interest groups were represented in forest plots with 95% confidence intervals (CI)[31]. Tau^2 was used to estimate of the between-study variance in a random-effects meta-analysis. Statistical heterogeneity across studies was assessed using chi-squared statistic (Chi^2) and the I^2 index. According to the Cochrane handbook, I^2 values of 25%, 50%, and 75% represented low, moderate, and substantial inter-study variability, respectively<sup>[32]</sup>. The Wan et al. method was employed to estimate the mean and standard deviation (SD) when studies provided median and interquartile range (IQR)<sup>[33]</sup>. All calculations were conducted using R statistical software (version 4.3.0).

# **Results**

# Study inclusions and quality assessment

The search syntax yielded 1165 publications, of which 275 were duplicates and 878 were excluded following abstract screening. Of the 22 entries that were eligible for full-text assessment, 12 studies were excluded for not complying with the eligibility criteria: Two studies were not based on a Chinese population; five did not provide specific diagnostic data for p-tau181; one did not use Simoa assays for measurement; and four had duplicated published data for the same baseline cohort. Consequently, 10 studies were included in this meta analysis. The detailed selection process is illustrated by the PRISMA flow diagram in Figure 1. The modified NOS criteria for quality assessment of the studies indicated that the majority of them were of high-quality (Table 1). One study scored low on the quality assessment since it only contained healthy cohort and lacked biomarker diagnosis for inclusion criteria. The characteristics of the 10 studies, including the number of subjects, average age, female percentage, and plasma p-tau181 level are presented in Table 2. From the included studies, 7 studies compared blood biomarkers between AD and healthy controls (783 AD patients and 508 controls), while four of them also focused on mild cognitive impairment (MCI) comparing 368 MCI patients and 321 controls. Six studies paid extra attention to the performance of plasma p-tau181 between 649 AD patients and 413 non-AD dementia patients (non-ADD), including patients with cognitive disorders other than AD, such as frontotemporal dementia, vascular dementia, Lewy body disease, and Parkinson's disease dementia.

[Figure 1 here]

#### Plasma p-tau181 levels in healthy cohorts

A summary of plasma p-tau181 levels in Chinese healthy cohorts was presented. 165

Subgroup analysis was performed according to age and sex ratio. The retrieved data

perpetuity.
All rights reserved. No reuse allowed without permission.

were stratified by mean age into two cohors: young (< 65 years) and old ( $\ge 65$  years). 167 The sex ratio was defined as medium (40-60% female) and high (more than 60% 168 female). Following the removal of one study (Chen J, et al 2023) with high 169 heterogeneity I<sup>2</sup> = 95%, seven studies were included, suggesting that the average 170 plasma p-tau181 level in Chinese healthy populations was 2.09 pg/ml (95% CI 171 172 1.90-2.30,  $I^2 = 77\%$ , P < 0.01) (Figure 2a). The mean plasma p-tau181 levels in young and old groups were 2.23 pg/ml (95% CI 1.66-3.00) and 2.03 pg/ml (95% CI 173 1.85–2.30), respectively, with no significant differences observed (p = 0.54) (Figure 174 2b). Nevertheless, there were significant differences (p = 0.04) in the subgroup 175 analyses by sex ratio. As illustrated in Figure 2c, the mean plasma p-tau181 176 concerntration was 1.87 pg/ml (95% CI 1.74-2.01) in the subgroup with more than 177 178 60% female participants, in comparison with 2.14 pg/ml (95% CI 1.92-2.37) in the 179 other subgroup.

[Figure 2 here]

# Plasma p-tau181 levels in AD patients

180

181

182

183

184

185

186

187

188 189

190

191 192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

A total of nine studies with 11 cohorts were conducted to evaluate p-tau181 plasma levels in 1131 AD patients. The results indicated a mean value of 4.48 pg/ml (95% CI 4.01-5.00,  $I^2 = 93\%$ , P < 0.01) (Figure 3a). The heterogeneity of observed in the data was influenced by a number of factors, including age and sex composition, geographic location of the study, time period and the severity of disease. Most of the studies included in the current analysis employed clinical diagnostic guidelines, including various iterations of international guidelines, rather than the gold standard of autopsy-confirmed AD, which may have contributed to the observed heterogeneity. There was significantly difference of plasma p-tau181 levels between young and old groups of AD patients (P < 0.05), with 4.94 pg/ml (95% CI 4.42–5.53) and 4.12 pg/ml (95% CI 3.66-4.63) in young and old groups, respectively (Figure 3b). While no significant differences (P = 0.7) in subgroup analysis by sex ratio (Figure 3c). Subsequently, plasma p-tau181 levels were compared between AD patients and healthy cohorts. The meta-analysis based on seven studies including 783 AD patients and 508 control participants, demonstrated that p-tau181 was significantly higher in AD in comparison to control (p < 0.01), providing a SMD of 1.45 (95% CI: 1.25, 1.65), with low heterogeneity ( $I^2 = 33\%$ ) (Figure 3d). In the aspect of differentiating AD patients from normal controls, three studies demonstrated the diagnostic accuracy of plasma biomarkers, as indicated by ROC curves. Chen et al. reported as AUC (Area Under the Curve) of 0.882 (95%CI: 0.79, 0.97) for p-tau181, which was higher than A $\beta$ 40, A $\beta$ 42 and GAFP, but was lower than A $\beta$ 42/A $\beta$ 40 (AUC = 0.998, 95%CI: 0.99-1.00). Sun et al. combined plasma markers including Aβ42/Aβ40, p-tau181 and neurofilament light protein (NfL), suggesting the best discriminative performance (AUC = 0.902) among of all single plasma biomarkers (p-tau181 AUC=0.773), with a sensitivity and specificity of 0.867 and 0.886, respectively. Wu et al. found that p-tau181 performed well in both early-onset AD (EOAD) and late-onset AD (LOAD) patients (AUC = 0.925 and 0.842, respectively) for the AD/control comparison. Three additional studies focused on the ability of p-tau181 plasma levels in AB PET perpetuity.
All rights reserved. No reuse allowed without permission.

scanning status prediction, with AUC values of 0.813 (Xiao Z, et al., 2023), 0.916 (Guo Y, et al., 2023) and 0.839 (Gao F, et al., 2023 - CANDI cohort). Gao et al. constructed a logistic regression (LR) model, which combined APOE-E4, plasma p-tau181, and serum glial fibrillary acidic protein (GFAP), resulting in an improvement in the AUC for distinguishing Aβ-PET status from 0.839 to 0.915. Subsequently, the efficacy of this LR model was demonstrated in both the CANDI and multi-center cohorts, showing superior performance compared to any of the blood biomarkers. Guo et al. found other plasma biomarkers including A\u00e340, A\u00e342, Aβ42/Aβ40 and Nfl, had relatively lower discriminative accuracy than p-tau181. Furthermore, the study reported that once the CSF A\u03b342/A\u03b340 ratio was positive, plasma p-tau181 began to increase significantly and continued to increase throughout the course of preclinical AD.

[Figure 3 here]

# Plasma p-tau181 in MCI patients

224 Four studies evaluated plasma p-tau181 levels in 368 patients with MCI, suggesting that the mean value was 2.86 pg/ml (95% CI 2.45–3.34,  $I^2 = 82\%$ , P < 0.01) (Figure 225 4a). Our further meta-analysis revealed that p-tau181 levels were significantly higher 226 in MCI patients compared with controls (SMD = 0.55, 95% CI: 0.31, 0.78, P < 0.01), 227 while exhibiting a lower concentration than that in AD patients (SMD = -0.88, 95% 228 CI: -0.93, -0.82, P < 0.01) (Figure 4b, 4c). One study (Wu X, et al. 2021) 229 230 demonstrated that p-tau181 exhibited a larger AUC than plasma t-tau, A\u00e340, A\u00e342 and Nfl, achieving an AUC of 0.702 (95% CI: 0.64, 0.764) for the amnestic MCI/Ctrl 231 comparison and 0.719 (95% CI: 0.661, 0.776) for the amnestic MCI/AD comparison. 232 The AUC of the amnestic MCI/Ctrl comparison was then improved to 0.789 (95%CI: 233 0.737, 0.841) through the application of a model comparising t-tau, A\u00e340, A\u00e342, 234 p-tau181, and NfL, in conjunction age, sex, and education years. 235

[Figure 4 here]

## Plasma p-tau181 between AD patients and non-AD dementia patients

Five studies with seven cohorts focused on the performance of plasma p-tau181 in distinguishing AD patients from non-AD dementia patients, demonstrating p-tau181 level was significantly higher in AD. Studies with small sample sizes were not included in the meta-analysis. Based on the meta-analysis results we proved that the average p-tau181 level in AD patients was significantly higher than in those non-ADD patients, providing a SMD of 1.12 (95% CI: 0.53,1.71, p<0.01) (Figure 5). Two studies reported that p-tau181 had a better performance in discriminating AD from non-ADD than Aβ42, Aβ42/40, GFAP and NfL, providing the AUC of 0.892 and 0.805 respectively<sup>[36-37]</sup>. Besides, the AUC was improved to 0.945 when combined with other plasma biomarker index (Aβ42/ Aβ40, NfL, GFAP) in Chen Y, et al. research.

210

211

212

213

214 215

216

217

218

219

220 221

222

223

236

237

238

239

240

241

242

243

244 245

246

247

# **Discussion**

250

251

271

281

291

The current investigation examined the conflicting results of studies on plasma p-tau181 linked to AD or MCI in the Chinese population, aiming to develop a 252 non-invasive diagnostic biomarker for the early phases of AD. Plasma p-tau181 levels 253 254 may serve as one of the most promising fluid biomarkers for validating AD or MCI diagnoses. The current findings show that AD is associated with higher blood levels 255 of p-tau181 compared to MCI and controls. Based on the current literature, we 256 established the average plasma p-tau181 levels for AD, MCI, and controls in the 257 Chinese population, providing reference values for future clinical diagnosis. 258 Many meta-analysis studies have demonstrated that plasma p-tau181 can precisely 259 260 differentiate AD from MCI and healthy controls. However, most of the studies were based on Western populations. It is validated that race and ethnicity have impact on 261 the level of p-tau181 in many studies. Howell et al. found that African Americans 262 showed lower p-tau181 levels in cerebrospinal fluid (CSF) than Caucasians, which 263 may lead to underdiagnosis of AD in African Americans<sup>[26]</sup>. Schindler et al. Further 264 validated that diagnosis performance of plasma p-tau181 in AD is inconsistent 265 between African (AA) and non-Hispanic White (NHW), which could result in 266 disproportionate misdiagnosis of AA individuals<sup>[38]</sup>. In the Canadian population, the 267 reference range for plasma p-tau181 is 0.9-4 pg/ml for individuals aged 60-80. In a 268 Japanese population study, the interquartile range (IOR) for plasma p-tau181 was 269 2.58-4.31 pg/ml in PET-positive cohorts, and 1.32-2.33 pg/ml in PET-negative 270 individuals. Additionally, a meta-analysis by Ding et al. showed that the average plasma p-tau181 level in the general population is 11.18 pg/ml<sup>[25]</sup>. This is significantly 272 273 different from the meta-analysis results for the Chinese population, which reported an average level of 2.09 pg/ml. This study was conducted among Chinese populations, 274 which further add to the evidence of plasma p-tau181 as reliable prognostic 275 candidates for AD and highlight their promising roles in future clinical practice and 276 research. Cooper et al. found in addition to population, p-tau181 levels are also 277 affected by other factors such as hypertension, myocardial infarction (MI) and 278 stroke<sup>[39]</sup>. More comprehensive studies are needed to determine the impact of these 279 factors on p-tau181 levels. 280 To improve diagnosis accuracy, the p-tau181 was combined with APOE genotyping, where the presence of an \(\epsilon\) allele (encoding the E4 isoform of the apoplipoprotein E 282 protein) is associated with higher probability of AD. Snellman et al. indicates that 283 plasma p-tau181 levels are significantly higher in APOE4/4 carriers compared to 284 non-carriers and heterozygous APOE3/4 carriers<sup>[40]</sup>. Elevated levels of plasma 285 p-tau181 are already observed in cognitively unimpaired high-risk individuals with 286 homozygous APOE4/4. Cooper et al suggests a strong correlation between p-tau181 287 levels and APOE & carrier status in cognitively healthy individuals over 85 years 288 old<sup>[39]</sup>. Although p-tau181 levels are elevated in elderly APOE & carriers, their 289 cognitive abilities remain intact. Combining APOE and p-tau181 markers and 290 conducting joint analyses may provide more comprehensive predictive information 292 for clinical diagnosis of Alzheimer's disease.

Compared to p-tau181, p-tau217 which is tightly associated with Ab plaque formation 293 within the brain, suggested a higher specificity to AD. Nervertheless, meta-analysis of 294 this biomarker could not be done due to too few studies, especially in Chines 295 population. Integration of diverse P-tau formed proteins such as p-tau181, p-tau217 296

and p-tau231 may significantly improved diagnosis power of AD<sup>[41]</sup>.

#### Limitations

297 298

299

300

301

302

303 304

305

306

307

308 309 310 Some limitations should be addressed in this meta-analysis. Firstly, misdiagnosis could have occurred in some of the studies included in this systematic review, as diagnosis was reached mostly on clinical grounds rather than gold-standard autopsy-confirmend AD. Secondly, only 10 studies were used for meta-analysis, this small studies can be more heterogeneous than large studies. These findings will be verified in future large and multicenter cohort studies for subsequent diagnosis for MCI and AD. Lastly, it is likely that the level of plasma p-tau181 is correlated with APOE status. However, due to lacking of these data, we can't explore the impact of APOE to levels of p-tau181 in different groups.

#### Conclusion

- In summary, our meta-analysis revealed significant relationships of plasma p-tau181 311
- 312 with Alzheimer's patients compared with cognitively normal control subjects and
- mild cognitive impairment. The results presented provide preliminary reference value 313
- of plasma p-tau181 for AD and MCI, which may facilitate clinical diagnosis of 314
- neurological diseases for Chinese population. 315
- Funding All authors acknowledge funding from Tianjin Science and Technology 316
- Leading Cultivation Enterprise Project (22YDPYSY0020). 317

#### **Authors' contributions**

- KQ Yan conceptualised this systematic review. SX He searched the literature and 319
- screened the titles and abstracts. KQ Yan and SX He reviewed all full-text articles and 320
- 321 extraced data. HY Li and XD Jia formally analysed, visualised and validated the data.
- DQ Liu and JC Chen supervised the systematic review. All authors were responsible 322
- for the methodology and review and editing of the manuscript. All authors had final 323
- responsibility for the decision to submit the manuscript for publication. 324

# References

- 327 [1]. Prince, M., et al., World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of
- prevalence, incidence, cost and trends.. 2015, Alzheimer's Disease International. 328
- 329 [2]. Tagarelli, A., et al., Alois Alzheimer: a hundred years after the discovery of the eponymous
- 330 disorder. International journal of biomedical science: IJBS, 2006. 2(2): p. 196.
- 331 [3]. McKhann, G.M., et al., The diagnosis of dementia due to Alzheimer's disease: Recommendations
- 332 from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for
- 333 Alzheimer's disease. Alzheimer's & dementia, 2011. 7(3): p. 263-269.
- 334 [4]. Albert, M.S., et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease:
- 335 recommendations from the National Institute on Aging-Alzheimer's Association workgroups on
- 336 diagnostic guidelines for Alzheimer's disease. Focus, 2013. 11(1): p. 96-106.
- 337 [5]. Sperling, R.A., et al., Toward defining the preclinical stages of Alzheimer 's disease:
- 338 Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on
- 339 diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia, 2011. 7(3): p. 280-292.
- 340 [6]. Braak, H. and E. Braak, Neuropathological stageing of Alzheimer-related changes. Acta
- 341 neuropathologica, 1991. 82(4): p. 239-259.
- 342 [7]. Chatterjee, P., et al., Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's
- 343 disease. Alzheimer's & Dementia, 2022. 18(6): p. 1141-1154.
- 344 [8]. Hansson, O., Biomarkers for neurodegenerative diseases. Nature medicine, 2021. 27(6): p.
- 345 954-963.
- 346 [9]. Mi, K. and G.V. Johnson, The role of tau phosphorylation in the pathogenesis of Alzheimer's
- 347 disease. Current Alzheimer Research, 2006. 3(5): p. 449-463.
- 348 [10]. Karikari, T.K., et al., Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a
- 349 diagnostic performance and prediction modelling study using data from four prospective cohorts. The
- 350 Lancet Neurology, 2020. 19(5): p. 422-433.
- 351 [11]. Thijssen, E.H., et al., Association of Plasma P-tau217 and P-tau181 with clinical phenotype,
- 352 neuropathology, and imaging markers in Alzheimer's disease and frontotemporal lobar degeneration: a
- 353 retrospective diagnostic performance study. The Lancet. Neurology, 2021. 20(9): p. 739.
- 354 [12]. Thomas, A.J., et al., A longitudinal study of plasma pTau181 in mild cognitive impairment with
- 355 Lewy bodies and Alzheimer's disease. Movement Disorders, 2022. 37(7): p. 1495-1504.
- 356 [13]. Tissot, C., et al., Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease.
- 357 Alzheimer's Research & Therapy, 2021. 13: p. 1-11.
- 358 [14]. Doecke, J.D., et al., Plasma pTau181 and biomarker combinations to identify Alzheimer's disease
- 359 at any stage along the AD continuum compared with both controls and non - AD dementia.
- 360 Alzheimer's & Dementia, 2023. 19: p. e077504.
- [15]. Coomans, E.M., et al., A head-to-head comparison between plasma ptau181 and tau pet along the 361
- 362 Alzheimer's disease continuum. Journal of Nuclear Medicine, 2023. 64(3): p. 437-443.
- 363 [16]. Rissin, D.M., et al., Single-molecule enzyme-linked immunosorbent assay detects serum proteins
- 364 at subfemtomolar concentrations. Nature biotechnology, 2010. 28(6): p. 595-599.
- 365 [17]. Janelidze, S., et al., Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers,
- 366 differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nature
- 367 medicine, 2020. 26(3): p. 379-386.
- 368 [18]. Karikari, T.K., et al., Diagnostic performance and prediction of clinical progression of plasma

- 369 phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Molecular psychiatry, 2021.
- 370 26(2): p. 429-442.
- 371 [19]. Chen, J., et al., Reference intervals for plasma amyloid- β, total tau, and phosphorylated tau181 in
- 372 healthy elderly Chinese individuals without cognitive impairment. Alzheimer's Research & Therapy,
- 2023. 15(1): p. 100. 373
- 374 [20]. Guo, Y., et al., The dynamics of plasma biomarkers across the Alzheimer 's continuum.
- 375 Alzheimer's Research & Therapy, 2023. 15(1): p. 31.
- 376 [21]. Sun, Q., et al., Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors
- 377 of probable Alzheimer's disease dementia in Chinese individuals. Frontiers in Aging Neuroscience,
- 378 2022. 14: p. 963845.
- 379 [22]. Cai, H., et al., Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese
- 380 cohorts. Nature Communications, 2023. 14(1): p. 6747.
- 381 [23]. Wu, X., et al., Development of a plasma biomarker diagnostic model incorporating ultrasensitive
- 382 digital immunoassay as a screening strategy for Alzheimer disease in a Chinese population. Clinical
- 383 Chemistry, 2021. 67(12): p. 1628-1639.
- 384 [24]. Gao, F., et al., Blood-based biomarkers for Alzheimer 's disease: a multicenter-based
- 385 cross-sectional and longitudinal study in China. Science Bulletin, 2023. 68(16): p. 1800-1808.
- 386 [25]. Ding, X., et al., Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in
- 387 Alzheimer's disease: a systematic review and meta-analysis. Translational neurodegeneration, 2021. 10:
- 388 p. 1-14.
- 389 [26]. Howell, J.C., et al., Race modifies the relationship between cognition and Alzheimer's disease
- 390 cerebrospinal fluid biomarkers. Alzheimer's research & therapy, 2017. 9: p. 1-10.
- 391 [27]. Jack Jr, C.R., et al., NIA-AA research framework: toward a biological definition of Alzheimer's
- 392 disease. Alzheimer's & dementia, 2018. 14(4): p. 535-562.
- 393 [28]. McKhann, G., et al., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS - ADRDA
- 394 Work Group\* under the auspices of Department of Health and Human Services Task Force on
- 395 Alzheimer's Disease. Neurology, 1984. 34(7): p. 939-939.
- 396 [29]. Wells, G.A., et al., The Newcastle-Ottawa Scale (NOS) for assessing the quality of
- 397 nonrandomised studies in meta-analyses. 2000.
- 398 [30]. Van Houwelingen, H.C., L.R. Arends and T. Stijnen, Advanced methods in meta - analysis:
- 399 multivariate approach and meta - regression. Statistics in medicine, 2002. 21(4): p. 589-624.
- 400 [31]. Friedrich, J.O., N.K. Adhikari and J. Beyene, The ratio of means method as an alternative to mean
- 401 differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC
- 402 Medical Research Methodology, 2008. 8: p. 1-15.
- 403 [32]. Higgins, J.P., et al., Measuring inconsistency in meta-analyses. Bmj, 2003. 327(7414): p. 557-560.
- 404 [33]. Wan, X., et al., Estimating the sample mean and standard deviation from the sample size, median,
- 405 range and/or interquartile range. BMC medical research methodology, 2014. 14: p. 1-13.
- 406 [34]. Chen, Y., et al., Diagnostic value of isolated plasma biomarkers and its combination in
- 407 neurodegenerative dementias: A multicenter cohort study. Clinica Chimica Acta, 2024. 558: p. 118784.
- 408 [35]. Huang, L., et al., Neuropsychiatric symptoms in Alzheimer's continuum and their association with
- 409 plasma biomarkers. Journal of Affective Disorders, 2024. 348: p. 200-206.
- 410 [36]. Shang, L., et al., Association of APOE & 4/ & 4 with fluid biomarkers in patients from the
- 411 PUMCH dementia cohort. Frontiers in Aging Neuroscience, 2023. 15: p. 1119070.
- 412 [37]. Xiao, Z., et al., Plasma p - tau217, p - tau181, and NfL as early indicators of dementia risk in a

413 community cohort: The Shanghai Aging Study. Alzheimer's & Dementia: Diagnosis, Assessment &

- 414 Disease Monitoring, 2023. 15(4): p. e12514.
- 415 [38]. Schindler, S.E., et al., Effect of race on prediction of brain amyloidosis by plasma A \( \beta \) 42/A \( \beta \) 40,
- 416 phosphorylated tau, and neurofilament light. Neurology, 2022. 99(3): p. e245-e257.
- 417 [39]. Mielke, M.M., et al., Performance of plasma phosphorylated tau 181 and 217 in the community.
- 418 Nature medicine, 2022. 28(7): p. 1398-1405.
- 419 [40]. Cooper, J.G., et al., APOE ε 4 carrier status modifies plasma p - tau181 concentrations in
- 420 cognitively healthy super - seniors. Alzheimer's & Dementia, 2024.
- [41]. Qu, Y., et al., Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and 421
- 422 Alzheimer's disease: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews,
- 423 2021. 128: p. 479-486.

424

# Table 1. Quality assessment of included studies in the meta-analysis using NEWCASTLE -OTTAWA QUALITY ASSESSMENT SCALE (NOS)

427

428

429 430 431

		Selection	on		Comparability	Exposure			
	Is the case definition adequate?	Representativeness of the cases	Selection of Controls	Definition of Controls	Comparability of cases and controls on the basis of the design or analysis	Ascertainment of exposure	Same method of ascertainment for cases and controls	Non-Response rate	
Chen J, et al. 2023	NA	NA		-	NA	*	NA	*	
Guo Y, et al. 2023	*	*	*	*	**	*	*	*	
Sun Q, et al. 2022	*	*	*	*	*	*	*	*	
Cai H, et al. 2023	*	*	*	*	*	*	*	*	
Wu X, et al. 2021	=	*	*	*	*	*		*	
Gao F, et al. 2023	*	*	*	*	*	*	*	*	
Chen Y, et al. 2024	*	*	*	*	*	*	*	*	
Huang L, et al. 2024	*	*	*	*	**	*	*	*	
Shang L, et al. 2023	*	*	*	*	*	*	*	*	
Xiao Z, et al. 2023	-	*	*	*	*	*	*	*	

Table 2. Basic characteristics of included studies for plasma p-tau181 analysis

Study	Subjects (n)	Female (%)	Age (years)	P-tau181 (pg/ml)
Chen J, et al. 2023 <sup>[19]</sup>	CN (193)	49.7	$67.3 \pm 9.8$	1.19 (0.88, 1.76)
	CN (43)	58.82	$57.02\pm6.76$	$1.92 \pm 0.78$
G V 1 2022[20]	MCI (36)	58.33	$66.72 \pm 9.82$	$2.88 \pm 1.70$
Guo Y, et al. 2023 <sup>[20]</sup>	AD (93)	59.14	$59.48 \pm 8.28$	$4.60\pm1.82$
	Non-AD dementia (68)	41.18	$62.41\pm8.70$	$2.08 \pm 1.16$
S 0 4 1 2022[71]	CN (44)	50	$71.86 \pm 7.76$	2.27 (1.78, 3.18)
Sun Q, et al. 2022 <sup>[21]</sup>	AD (30)	40	$75.27\pm7.67$	3.94 (3.02, 5.39)
G : H + 1 2022[22]	CN (123)	50.4	$70.0 \pm 7.1$	1.9 (1.51, 2.67)
Cai H, et al. 2023 <sup>[22]</sup>	AD (126)	50	$69.0 \pm 6.3$	$3.97\pm1.39$
	CN (121)	62.8	$69.3 \pm 7.1$	1.8 (1.4, 2.4)
Wu X, et al. 2021 <sup>[23]</sup>	MCI (148)	54.1	$69.7 \pm 8.8$	4.3 (3.0, 5.6)
	AD (159)	57.2	$66.9 \pm 9.9$	2.6 (1.7, 3.9)
	CN (104)	52.9	$59.1 \pm 8.6$	$2.6\pm1.8$
Gao F, et al. 2023 - CANDI	MCI (110)	62.7	$63.3 \pm 9.3$	$3.5\pm2.3$
cohort <sup>[24]</sup>	AD (208)	63.9	$63.0 \pm 8.1$	$5.8\pm2.8$
	Non-AD dementia (55)	49.1	$61.9 \pm 8.1$	$3.5\pm2.8$
C F 4 1 2022 WOW 1 4 1741	AD (47)	57.4	$76.8 \pm 6.0$	$5.8 \pm 3.0$
Gao F, et al. 2023 - WCH cohort <sup>[24]</sup>	Non-AD dementia (81)	58.0	$60.9 \pm 7.4$	$2.9\pm1.0$
Gao F, et al. 2023 - SAHZU	AD (36)	66.7	$61.9 \pm 9.6$	$4.1\pm1.6$
cohort <sup>[24]</sup>	Non-AD dementia (19)	31.6	$60.4 \pm 9.8$	$3.5\pm1.9$
	CN (20)	50	$65.7 \pm 9.1$	1.8 (1.4, 2.4) 4.3 (3.0, 5.6) 2.6 (1.7, 3.9) 2.6 $\pm$ 1.8 3.5 $\pm$ 2.3 5.8 $\pm$ 2.8 3.5 $\pm$ 2.8 5.8 $\pm$ 3.0 2.9 $\pm$ 1.0 4.1 $\pm$ 1.6
Class V at al. 2024[34]	AD (64)	48.44	$62.8 \pm 10.7$	5.2 (3.8, 7.1)
Chen Y, et al. 2024 <sup>[34]</sup>	FTD (16)	62.5	$64.3 \pm 9.0$	2.9 (2.2, 5.0)
	PSP (12)	58.33	$71.8 \pm 5.9$	2.9 (1.5, 3.2)
	CN (53)	45.28	$65.13\pm6.96$	$1.93\pm0.90$
Huang L, et al. 2024 <sup>[35]</sup>	MCI (74)	48.65	$65.72\pm6.60$	$2.43\pm1.44$
	AD (103)	59.22	$66.03\pm8.21$	$3.95\pm1.94$

Study	Subjects (n)	Female (%)	Age (years)	P-tau181 (pg/ml)
Chang I at al 2022[36]	AD (120)	55.8	$60.8 \pm 7.9$	$4.9\pm1.9$
Shang L, et al. 2023 <sup>[36]</sup>	Non-AD dementia (128)	46.9	$61.7 \pm 9.1$	$2.7\pm1.4$
W: 7 + 1 2022[37]	AD (145)	62.1	$79.1 \pm 6.1$	$3.12\pm2.30$
Xiao Z, et al. 2023 <sup>[37]</sup>	Non-AD dementia (62)	71	$77.8 \pm 5.9$	$2.22\pm0.80$

# **Figures**

435 436

437 438

439

Figure 1. PRISMA flow diagram of study selection process




Figure 2. Forest plot of random effects meta-analysis of plasma p-tau181 levels in 440 healthy controls (A), age subgroups (B) and sex ratio subgroups (C). 441

All rights reserved. No reuse allowed without permission.




Figure 3. Forest plot of random effects meta-analysis of plasma p-tau181 levels in AD patients (A), age subgroups (B) and sex ratio subgroups (C). Meta-analysis of studies comparing p-tau181 levels between AD and healthy controls (D).

442

443444

All rights reserved. No reuse allowed without permission.




Figure 4. Forest plot of random effects meta-analysis of plasma p-tau181 levels in MCI patients (A), age subgroups (B) and sex ratio subgroups (C).

446

447448




Figure 5. Forest plot of random effects meta-analysis of plasma p-tau181 levels in AD and non-AD patients.

Study	Mean	AD SD		No Mean	n-ADD SD		Weight	Std. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% CI
O F -+ -1 0000 (OAND)	5.00	0.0000	000	0.50	0.0000		00.40/	0.00.00.54.4.401	
Gao F, et al. 2023 (CANDI)		2.8000	208		2.8000	15.0	20.4%		
Gao F, et al. 2023 (WCH)	5.80	3.0000	47	2.90	1.0000	81	18.9%	1.46 [1.05, 1.86]	÷ +
Guo Y, et al. 2023	4.60	1.8200	93	2.08	1.1600	68	19.6%	1.59 [1.23, 1.95]	-   -   -   -   -   -   -   -   -   -
Shang L, et al. 2023	4.90	1.9000	120	2.70	1.4000	128	20.8%	1.32 [1.05, 1.60]	÷ -
Xiao Z, et al. 2023	3.12	2.3000	145	2.22	0.8000	62	20.4%	0.45 [0.15, 0.75]	-
Total (95% CI)			613			394	100.0%	1.12 [0.53, 1.71]	
Heterogeneity: Tau2 = 0.20; C	$hi^2 = 33$	56 df =	4 (P <	0.01): [	$^{2} = 88\%$				
Test for overall effect: $t_4 = 5.25 (P < 0.01)$								-1 0 1	